All In Biotech

Drug Trial Radar · NCT06505824

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Aug 2, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M14D1 in locally advanced or metastatic solid tumors.

Conditions

  • Small Cell Lung Cancer
  • Neuroendocrine Tumors

Interventions

  • BL-M14D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
  3. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.